Paper Details

  1. Home
  2. Paper Details

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.

Author: AlvarezEnrique, BaggerMorten, Bar-OrAmit, DavydovskayaMaria, DelgadoSilvia R, EvdoshenkoEvgeniy P, FoxEdward J, GiedraitieneNatasa, Gross-PajuKatrin, HaldreSulev, HerrmanCraig E, HäringDieter A, IzquierdoGuillermo, KarelisGuntis, LeutmezerFritz, LudwigInga, MaresMiroslav, Meca-LallanaJose E, MerschhemkeMartin, MickevicieneDalia, MontalbanXavier, NicholasJacqueline, RobertsonDerrick S, SazonovDenis V, SharlinKenneth, SuWendy, SundaramBharathy, TotolyanNatalia, VachovaMarta, ValisMartin, WiendlHeinz, WilliRoman, ZalesakMartin

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A phase 2 study of 256 patients with relapsing multiple sclerosis (RMS) demonstrated bioequivalence between ofatumumab administered via autoinjector and pre-filled syringe (PFS) for subcutaneous administration. Both methods achieved rapid B-cell depletion.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, is approved in several countries for relapsing multiple sclerosis (RMS). OBJECTIVE: To demonstrate the bioequivalence of ofatumumab administered by an autoinjector versus a pre-filled syringe (PFS) and to explore the effec...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024029/

データ提供：米国国立医学図書館（NLM）

Ofatumumab: A Camel's Perspective on Multiple Sclerosis Treatment

The world of multiple sclerosis (MS) is a complex and challenging landscape, with researchers constantly seeking new and effective treatments. This research explores the efficacy and safety of ofatumumab, a medication used to treat relapsing MS, when administered subcutaneously using an autoinjector versus a pre-filled syringe. It's like comparing two different camel saddles, evaluating their comfort and effectiveness in navigating the desert of MS.

The study found that ofatumumab delivered by an autoinjector is bioequivalent to the pre-filled syringe method, providing rapid B-cell depletion. It's like discovering that two different camel saddles can both provide a smooth and efficient journey through the desert.

A Smoother Journey Through the Desert of MS

The findings suggest that the autoinjector offers a convenient and effective option for patients receiving ofatumumab therapy. This is like finding a new oasis in the desert of MS treatment, offering a more comfortable and efficient way to access care.

A Camel's Guide to MS Treatment

If you're living with MS, discuss the various treatment options and their potential benefits and risks with your doctor. It's like consulting a wise camel guide, ensuring that you choose the best path for your specific journey.

Dr. Camel's Conclusion

This research is a testament to the ongoing progress in the field of MS treatment. It's like finding a new, more comfortable camel saddle, making the journey through the desert of MS a little easier and more manageable.

Date :
  1. Date Completed 2022-04-21
  2. Date Revised 2022-07-16
Further Info :

Pubmed ID

34605319

DOI: Digital Object Identifier

PMC9024029

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.